Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (24580)	8/16/1998 10:16:00 PM
From: Henry Niman	Respond to of 32384

Bob, The first part of your revenue question has already been asked and answered. On Aug 4 LGND indicated that the 2nd half of 1998 would be considerably better than the first half. The potential milestone list is long, and much should happen this year. Among the potential milestone payments are, LLY for starting a US Targretin diabetes trial, LLY for filing an IND for LGD1268 or LGD1324, AHP for filing an IND for a cancer fighting SERM, ABT for filing an IND for a GR modulator, GLX for filing an IND for one or more compounds targeting atherosclerosis or lipid metabolism. I'm not sure about PFE for advancing Droloxifene or CP-366,156 and there may be something associated with SRGN deals.